Call +41-61-926-60-40 Fax +41-61-926-60-49

IL-37 (human) ELISA Kit

AG-45A-0041YEK-KI01 96 wells INQ
AG-45A-0041YTP-KI01 2 x 96 wells INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!

Additional Information

Product Data
Synonyms Interleukin-1 Family Member 7; IL-1F7; FIL1 zeta; IL-1X; Interleukin-1 Homolog 4; IL-1H4; Interleukin-1 zeta; IL-1 zeta; IL-1RP1; IL1F7; FIL1Z, IL1H4, IL1RP1
Properties
Application Quantitative ELISA
Specificity Detects human IL-37 (monomeric and dimeric forms). Does not cross-react with human IL-33, IL-38, IL-6, IL-23, IL-24 or mouse IL-33 and IL-38.
Crossreactivity Human
Quantity 1 x 96 wells
2 x 96 wells (Twin Plex)
Sensitivity 10pg/ml
Range 0.016 to 1ng/ml
Sample Type Plasma, Serum
Assay Type Sandwich
Detection Type Colorimetric
Product Type Kit
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice After standard reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Plate and reagents should reach room temperature before use.
Use/Stability 12 months after the day of manufacturing. See expiry date on ELISA Kit box.
Documents
Manual Download Document Download
MSDS Download Document Download
Related Products

Product Description

IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption. A recent study indicates that IL-37 protein forms a head-to-head homodimer and this structure limits its bioactivity. Variants with mutations converting the cytokine into a monomeric form are 13 fold more active than the dimeric IL-37.

Product References

  1. Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment: C. Li, et al.; J. Interferon Cytokine Res. 33, 612 (2013)
  2. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome: C. Li, et al.; Mediators Inflamm. 2013, 639712 (2013)
  3. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity: L. Ye, et al.; J. Transl. Med. 12, 69 (2014)
  4. Plasma Levels of IL-37 and Correlation with TNF-α, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis: P.-W. Zhao, et al.; PLOS One 9, e95346 (2014)
  5. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis: P. Italiani, et al.; J. Neuroinflamm. 11, 94 (2014)
  6. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome: Q. Ji, et al.; Mediat. Inflamm. 2014, ID165742 (2014)
  7. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity: B. Chen, et al.; J. Transl. Med. 13, 36 (2015)
  8. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer: G. Ge, et al.; J. Exp. Clin. Cancer Res. 35, 13 (2016)
  9. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus: J. Godsell, et al.; Sci. Reports 6, 34604 (2016)
  10. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients: J. Huo, et al.; Arch. Gynecol. Obstet. 295, 459 (2017)
  11. Interleukin-37 elevation in patients with atrial fibrillation: W. Li, et al.; Clin. Cardiol. 40, 66 (2017)
  12. Homodimerization attenuates the anti-inflammatory activity of interleukin-37: A.M. Ellisdon, et al.; Sci. Immunol. 2, eaaj1548 (2017)
  13. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification: M. Chai, et al.; J. Geriatr. Cardiol. 14, 285 (2017)
  14. IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction: K. Liu, et al.; Clin. Chim. Acta 468, 140 (2017)
<b>Standardcurve</b>
Standardcurve
No reviews for this product yet.